BioPharma Resources

Drug Trial Radar · NCT04417517

A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)

A Phase 1/2 Study of Evorpacept (ALX148) in Combination With Azacitidine in Patients With Higher Risk Myelodysplastic Syndrome (MDS) (ASPEN-02)

Last checked: Nov 19, 2026Latest source record: Jul 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Terminated

Status

Terminated

Enrollment

65

Actual

Start

Oct 2, 2020

Primary completion

Jan 17, 2025

Study completion Jun 10, 2025

Sponsor

Lead sponsor
ALX Oncology Inc.Industry
Sponsor type
Industry
First posted
Jun 4, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This Phase 1/2 clinical study will evaluate evorpacept (ALX148) in combination with azacitidine for the treatment of patients with higher risk myelodysplastic syndrome (MDS).

Conditions

  • Higher Risk Myelodysplastic Syndromes

Interventions

  • evorpaceptDrug

    Fusion protein that blocks CD47-SIRPalpha pathway

  • azacitidineDrug

    Hypomethylating agent (HMA)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1: Dose Limiting Toxicities (DLT)Time frame: Up to 28 days
  2. Phase 1: Recommended Phase 2 Dose (RP2D)Time frame: Approximately 2 years
  3. Phase 2: Complete response rate (CRR)Time frame: Approximately 6 months

Locations

19 sites in 3 countries. Site status is shown where the registry gives one.

  • University of Southern California, Norris Comprehensive Cancer Center

    Los Angeles, California

  • Northwestern University Feinberg School of Medicine

    Chicago, Illinois

  • IU Simon Cancer Center

    Indianapolis, Indiana

  • START Midwest

    Grand Rapids, Michigan

  • Mayo Clinic

    Rochester, Minnesota

  • Levine Cancer Institute

    Charlotte, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • University of Texas MD Anderson Cancer Center

    Houston, Texas

  • Fred Hutchinson Cancer Research Center

    Seattle, Washington

  • Asan Medical Center

    Seoul, South Korea

  • Samsung Medical Center

    Seoul, South Korea

  • Seoul National University Hospital

    Seoul, South Korea

  • Seoul Saint Mary's Hospital

    Seoul, South Korea

  • Severance Hospital

    Seoul, South Korea

  • Hospital General Universitario de Alicante

    Alicante, Spain

  • Hospital San Pedro de Alcantara

    Cáceres, Spain

  • Hospital Universitario de Salamanca

    Salamanca, Spain

  • Hospital Universitari i Politecnic La Fe de Valencia

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.